Scott Weiner


Broad transaction experience and a wide network enable Scott to provide assistance to companies when raising capital, forming strategic partnerships and analyzing exit options.

Prior to joining Pappas Capital in 2006, Scott was an investment manager and research analyst for Silverback Asset Management’s life science fund, where he focused on healthcare securities investing. Before joining Silverback, he spent three years at Chicago Growth Partners focused on healthcare venture investments, and prior to that, he spent three and a half years in investment banking at Lehman Brothers where he worked in New York, London and Hong Kong.

Scott currently serves as a director for Reneo Pharmaceuticals, and as an observer for 4D Molecular Therapeutics, Envisia Therapeutics, IlluminOss Medical, Liquidia Technologies, Milestone Pharmaceuticals, Thrasos Therapeutics and VelosBio. He previously served as a director for Rotation Medical (acquired by Smith & Nephew), and as an observer for LipoScience (NASDAQ: LPDX) (acquired by LabCorp) and TESARO (NASDAQ: TSRO). Scott is also a board member for the Council for Entrepreneurial Development (CED) and a member of the Investor Advisory Board of the Florida Institute for the Commercialization of Public Research.


Duke University (BS in Biological Anthropology and Anatomy)
Duke University Fuqua School of Business (MBA)

“Success in the life sciences venture business is primarily driven by people - those you invest in and those you invest with.”  

Serves as a Director for:

Serves as an Observer for:


  • Board Member, Council for Entrepreneurial Development (CED)
  • Investor Advisory Board Member, Florida Institute for the Commercialization of Public Research